Active Ingredient History
Ulinastatin, is a glycoprotein that is isolated from healthy human urine or synthetically produced and has molecular weight of 25 - 40kDa. It acts as a urinary trypsin inhibitor (UTI). Highly purified ulinastatin has been clinically used for the treatment of acute pancreatitis, chronic pancreatitis, Stevens–Johnson syndrome, burns, septic shock, and toxic epidermal necrolysis (TEN). Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Aortic Valve Disease (Phase 4)
Cardiopulmonary Bypass (Phase 4)
Cardiovascular Diseases (Phase 4)
Coronary Artery Disease (Phase 4)
COVID-19 (Phase 1/Phase 2)
Healthy Volunteers (Phase 1)
Heart Defects, Congenital (Phase 4)
Inhalation Exposure (Phase 2)
Mucositis (Phase 3)
Multiple Organ Failure (Phase 4)
Pancreatitis (Phase 4)
Pneumonia, Ventilator-Associated (Phase 2/Phase 3)
Respiratory Distress Syndrome (Phase 2)
Sepsis (Phase 4)
Shock, Septic (Phase 4)
Thoracic Surgery (Phase 4)
Ventilators, Mechanical (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue